Last reviewed · How we verify
GIK solution
At a glance
| Generic name | GIK solution |
|---|---|
| Also known as | Glucose-Insulin Potassium, glucose-insulin-potassium(GIK) solution, Glucose-insulin-potassium |
| Sponsor | Sohag University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- MAGIK for Femoral/Tibial Shaft Fractures (PHASE2)
- The Primary Objective of This Study Was to Investigate the Effect of Insulin on Myocardial Perfusion and Cardiac Function in Patients Undergoing Cardiac Surgery for CPB Using Transesophageal Echocardiography (TEE) to Detect CSBF (NA)
- Rapid Administration of Insulin in Sepsis (PHASE1)
- The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery (NA)
- IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium. (PHASE3)
- Reappraisal of GIK in Acute STEMI by Pre-hospital Administration (PHASE3)
- Benefits of GIK in Cardiac Surgery Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GIK solution CI brief — competitive landscape report
- GIK solution updates RSS · CI watch RSS
- Sohag University portfolio CI